Xencor: J&J's Janssen Termintates Rights to Plamotamab
By Colin Kellaher
Xencor on Thursday said Johnson & Johnson's Janssen unit has terminated its rights to the tumor-targeted antibody plamotamab under a collaboration and license agreement the companies inked in 2021.
Xencor said it will regain exclusive worldwide rights to plamotamab, which the Pasadena, Calif., clinical-stage biopharmaceutical company has advanced through Phase 1 clinical development in hematologic cancers.
Xencor said its CD28 bispecific antibody platform remains the subject of two collaborations with Janssen, JNJ-9401 and JNJ-1493, which the J&J unit is developing in prostate cancer and B-cell malignancies, respectively.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 13, 2024 08:44 ET (12:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks